A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)

International Journal of Lung Cancer · Elsevier

Аннотация

Publication date: September 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 3 Author(s): Kota Kawabata, Keita Miura, Yasushi Goto, Yoshimasa Shiraishi, Shogo Nomura, Noriko Mitome, Haruhiko Fukuda, Isamu Okamoto, Hirotsugu Kenmotsu, the Lung Cancer Study Group of the Japan Clinical Oncology Group

Читать у издателя →

Похожие статьи